Advances in the treatment of melasma: a review of the recent literature.

Katharine L Ball Arefiev, Basil M Hantash

Journal: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2012;38(7 Pt 1):971-84

PMID: 22583339

Abstract

BACKGROUND

Melasma is an acquired pigmentary disorder classically manifesting as symmetric hyperpigmented macules and patches on the face. It most commonly affects women of reproductive age with darker skin tones but may also affect adolescents, older women, and men. Although its pathogenesis remains unclear, known risk factors include ultraviolet radiation, hormonal variations of pregnancy, thyroid disease, oral contraceptives, and antiseizure medications. Hydroquinone-containing topical agents are the current standard for melasma treatment, but concern about side effects and long-term safety has spurred efforts to develop alternative treatment options.

OBJECTIVES

To review recent advances in melasma treatment.

MATERIALS AND METHODS

MEDLINE was searched from 2006 to the present for randomized controlled trials (RCTs) of melasma treatments.

RESULTS

Nineteen published RCTs were found covering interventions such as topical therapies, chemical peels, and electromagnetic devices. The outcomes of the studies were summarized into tabular form for easy reference and comparison.

CONCLUSIONS

Although melasma is difficult to treat, novel therapeutic modalities have emerged. Further RCT need to be performed to better assess the safety and efficacy of these novel treatment modalities, especially for the long-term maintenance of melasma.

© 2012 by the American Society for Dermatologic Surgery, Inc. Published by Wiley Periodicals, Inc.

Address: Department of Dermatology, Stanford University Medical Center, Stanford, California, USA.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.